Mechanism-selective inhibition of α-synuclein aggregation by the chaperone-like BRICHOS domain
Laurène Adam, Willem Hendrik Molenkamp, Jan Stanislaw Nowak, Azad Farzadfard, Koen Gaarthuis, Rakesh Kumar, Janni Nielsen, Daniel E Otzen, Jan Johansson, Axel Abelein · 2026
Read Mechanism-selective inhibition of α-synuclein aggregation by the chaperone-like BRICHOS domain by Laurène Adam, Willem Hendrik Molenkamp, Jan Stanislaw Nowak, Azad Farzadfard, Koen Gaarthuis, Rakesh Kumar, Janni Nielsen, Daniel E Otzen, Jan Johansson, Axel Abelein (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13254603.txt.
Description
Laurène Adam and co-authors studied a chaperone domain in 2026 that blocks clumping of a Parkinson's-linked protein. Current Parkinson's drugs ease symptoms without slowing the disease, so clump blockers are sought. The BRICHOS domain had blocked the human protein's clumping, but mouse tests come first in drug development.
On the mouse version of the protein, the blocker worked only weakly, and only under gentle conditions. Binding to finished fibres was similar for both species. The gap traced to how fibres grow: mouse fibres break apart more easily, feeding growth by fragmentation, while human growth runs mainly through surface-catalysed seeding, the step the blocker stops. Model choice for animal tests must respect this split, they warn.
Catalog record
| CREATOR | Laurène Adam, Willem Hendrik Molenkamp, Jan Stanislaw Nowak, Azad Farzadfard, Koen Gaarthuis, Rakesh Kumar, Janni Nielsen, Daniel E Otzen, Jan Johansson, Axel Abelein |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |